|

Breast Cancer Clinical Trials in North Carolina

123 recruiting studies across 2 cities

Browse by City

Raleigh
99 trials
Charlotte
41 trials

All Trials in North Carolina

Phase
Trial Phase Dist.
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyPhase 2<1 mi
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3<1 mi
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerPhase 3<1 mi
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Phase 3<1 mi
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic TherapyN/A<1 mi
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerPhase 3<1 mi
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerPhase 3<1 mi
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerPhase 1/2<1 mi
E-Mindfulness Approaches for Living After Breast CancerPhase 3<1 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3<1 mi
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Phase 3<1 mi
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerPhase 1/2<1 mi
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerPhase 1/2<1 mi
The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyPhase 3<1 mi
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerPhase 2<1 mi
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3<1 mi
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesPhase 1/2<1 mi
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPhase 3<1 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3<1 mi
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and MelanomaPhase 1<1 mi
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerPhase 3<1 mi
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Phase 3<1 mi
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)—<1 mi
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationPhase 1<1 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—<1 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3<1 mi
Utility of a Mobile Application for Young Women With Breast CancerN/A<1 mi
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerN/A<1 mi
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyPhase 3<1 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—<1 mi
ATEMPT 2.0: Adjuvant T-DM1 vs THPhase 2<1 mi
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPhase 3<1 mi
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPhase 2<1 mi
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCAN/A<1 mi
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialPhase 3<1 mi
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Phase 35 mi
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Phase 38 mi
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerPhase 311 mi
Study of XB010 in Subjects With Solid TumorsPhase 113 mi
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasPhase 113 mi
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsPhase 1/213 mi
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanPhase 113 mi
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsPhase 1/213 mi
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsPhase 113 mi
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPhase 1/213 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 320 mi
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/A20 mi
Increasing Germline Genetic Testing for Patients With CancerN/A21 mi
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H MutationPhase 121 mi
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationPhase 1/221 mi
Engage Psychosocial Intervention for Cancer SymptomsN/A21 mi
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerPhase 1/221 mi
A Phase 1/1b Study of IAM1363 in HER2 CancersPhase 121 mi
Optimizing Surgical Decisions in Young Adults With Breast CancerN/A21 mi
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer SurvivorsN/A21 mi
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring—21 mi
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)Phase 2/321 mi
The Vanguard Study: Testing a New Way to Screen for CancerN/A21 mi
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentPhase 221 mi
A Study of a Decision Tool for People Considering Breast Reconstruction SurgeryN/A21 mi
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePhase 321 mi
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast CancersPhase 221 mi
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationPhase 321 mi
Identifying Patterns in the Breath of Individuals With Breast Cancer—21 mi
Targeted Palliative Care Intervention for Patients With Metastatic Breast CancerN/A21 mi
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsPhase 121 mi
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Phase 1/221 mi
A Study of LY4337713 in Participants With FAP-Positive Solid TumorsPhase 121 mi
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary SurgeryN/A21 mi
Phase IIIb Study of Ribociclib + ET in Early Breast CancerPhase 321 mi
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEsPhase 221 mi
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsPhase 121 mi
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast CancersN/A21 mi
Weight Management After Cancer for Survivors in Rural CommunitiesN/A21 mi
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPhase 1/221 mi
Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast ReconPhase 121 mi
Behavioral Pain Intervention for Older Cancer PatientsN/A21 mi
Asciminib in HER2+ Breast Cancer Brain MetastasesPhase 1/221 mi
Planning Grant for TOPS for Breast Cancer SurvivorsN/A21 mi
Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With TucatinibN/A21 mi
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400Phase 121 mi
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation—23 mi
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)N/A25 mi
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T CellsPhase 125 mi
Nutrition Awareness Among Women With Non-Metastatic Breast CancerN/A25 mi
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast CancerPhase 225 mi
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study—25 mi
A Study of NX-1607 in Adults With Advanced MalignanciesPhase 125 mi
BREAST Choice Decision Tool R21 - AIM2N/A25 mi
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)Phase 225 mi
A Novel Approach Utilizing Organ Specific Age Proteomics—25 mi
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior—25 mi
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) ImagingPhase 225 mi
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer—25 mi
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast CancerPhase 225 mi
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdPhase 225 mi
Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase ExerciseN/A25 mi
Dissemination of BREASTChoice AIM1-BN/A25 mi
UNC Pleural Fluid Registry—25 mi
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerPhase 225 mi
VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients—25 mi
Low Dose Aspirin for the Prevention of Postpartum Related Breast CancerPhase 225 mi
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast CancerPhase 125 mi
PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients—25 mi
ETHAN - ET for Male BCPhase 225 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—25 mi
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCPhase 225 mi
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 YearsPhase 425 mi
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians—25 mi
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After LumpectomyPhase 225 mi
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and SurvivalN/A25 mi
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast CancerN/A25 mi
PREDICT-RD: ctDNA Surveillance in TNBC With Residual DiseasePhase 225 mi
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast CancerPhase 225 mi
Evolutionary Clinical Trial for Novel Biomarker-Driven TherapiesPhase 225 mi
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerPhase 225 mi
Pharmacologic Therapies to Mitigate Radiation- Associated Heart DiseasePhase 225 mi
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.Phase 341 mi
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsPhase 1/241 mi
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPhase 141 mi
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseasePhase 341 mi
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.Phase 441 mi
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityPhase 345 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.